PhRMA
SEPTEMBER 20, 2022
World Trade Organization (WTO) members, including the United States, are considering waiving commitments to honor certain intellectual property (IP) rights on COVID-19 treatments, following a harmful and unnecessary decision to do the same for COVID-19 vaccines. This is referred to as the TRIPS waiver.
Drug Topics
SEPTEMBER 17, 2022
Big data and analytics are everywhere—including in independent pharmacy. But is the collected information being used to help with documentation, care planning, and reimbursement?
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmacy Times
SEPTEMBER 20, 2022
Research suggests cannabis can improve quality of life for patients who suffer from pain and neurological disorders.
Pharmaceutical Technology
SEPTEMBER 22, 2022
It is the year 2030. You have just received the results from your whole genome sequencing test, offered through your public health provider, and discovered that you have a 75% chance of developing a rare form of cancer. But you are not panicking; your genomic data was automatically uploaded, with your permission, to your electronic health record (EHR), which is fully secured with blockchain technology.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
PhRMA
SEPTEMBER 23, 2022
September is National Sickle Cell Awareness Month and a time for us to underscore the biopharmaceutical industry’s ongoing commitment to improve the lives of patients, families and communities affected by sickle cell disease.
Drug Topics
SEPTEMBER 20, 2022
Distinctions between vaccine types are explored, as well as considerations such as egg-based allergies.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
STAT
SEPTEMBER 22, 2022
The National Institutes of Health on Thursday announced more than $600 million in fresh funding for an expansive and ongoing push to unravel the mysteries of the human brain, bankrolling efforts to create a detailed map of the whole brain, and devise new ways to target therapeutics and other molecules to specific brain cell populations. Scientists across the country are involved, from teams at the Salk Institute to Duke University to the Broad Institute of MIT and Harvard, among other places.
PhRMA
SEPTEMBER 23, 2022
Through the constant efforts of U.S. innovators and their global partners, COVID-19 treatments have continued to be distributed to patients around the world — changing the pandemic’s treatment landscape and the trajectory of the virus’ impact. This is in no small part due to the more than 140 collaborations for COVID-19 treatments that have been signed since the start of the pandemic, as reported to PhRMA by global data provider Airfinity.
Drug Topics
SEPTEMBER 22, 2022
Modeling indicates a significant increase in patients with type 1 diabetes over the next several years.
Pharmacy Times
SEPTEMBER 20, 2022
Researchers will submit a new drug application to the FDA after a phase 3 trial found that iDose TR slow- and fast-release models met their primary endpoint in patients with glaucoma.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
NF2 BioSolutions
SEPTEMBER 21, 2022
We have been very busy organising the NF Community Day in Manchester with other NF organisations and in particular NF Patients United. Registration for the NF Community Day is now open from Sept 20th 2022! You MUST register & sign up via this link: [link]. There is a maximum of 100 registration places available. Location: Mercure Manchester Piccadilly Hotel, £5 Per person attending.
STAT
SEPTEMBER 21, 2022
The short history of CRISPR gene editing in humans has, with rare exception, been a history of triumphant progress: A patient apparently cured of sickle cell in 2019, six patients with toxic DNA knocked out of their liver last year, another six patients with a different strand of toxic liver DNA knocked out last week. The next era of CRISPR may not be so smooth.
Drug Topics
SEPTEMBER 19, 2022
ViiV Healthcare reports long-term positive results for its drug, Rukobia (fostemsavir).
Pharmacy Times
SEPTEMBER 20, 2022
Second- and third-generation individuals living in Los Angeles, California, demonstrate 35% and 61%, respectively, more of a chance of getting the disease, according to new study results.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Pharmaceutical Technology
SEPTEMBER 23, 2022
Pfizer has entered an agreement with Global Fund to deliver up to six million courses of its oral therapy, Paxlovid (nirmatrelvir tablets and ritonavir tablets), under the Covid-19 Response Mechanism (C19RM). The C19RM has been the main channel to support low- and middle-income nations in procuring Covid-19 therapies, personal protective equipment, tests and vital elements to bolster health systems.
pharmaphorum
SEPTEMBER 21, 2022
The European Commission has followed the lead of the US FDA and approved AstraZeneca’s Tezspire as an add-on maintenance therapy for patients with severe asthma, becoming the first and only biologic that can be used in all patients, and not restricted to those with specific forms of the disease. Tezspire (tezepelumab) has been cleared for use in patients 12 years and older with severe asthma who are inadequately controlled with high dose inhaled corticosteroids plus another medicinal produ
Drug Topics
SEPTEMBER 23, 2022
Thousands of pharmacy professionals use SureCost every day to save. We examined their anonymized data to uncover five unique savings opportunities. Now, we've summarized these findings so that you can download our report.
Pharmacy Times
SEPTEMBER 21, 2022
On this month's episode hosts Jeremy Sasser and Jessica Langley-Loep from the National Healthcareer Association welcome their guest Christine Cline-Dahlman, BFA, CPhT, the founder and owner of PharmTechForward.
Pharmaceutical Technology
SEPTEMBER 19, 2022
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorisation for AstraZeneca ’s Evusheld (formerly AZD7442) for Covid-19 in the European Union (EU). This therapy is intended to treat adult and adolescent Covid-19 patients aged 12 years and above, who do not need additional oxygen and are at greater disease progression risk.
pharmaphorum
SEPTEMBER 20, 2022
Findings from the litifilimab trial, undertaken by Northwell Health’s Division of Rheumatology and The Feinstein Institutes for Medical Research, have been published in the New England Journal of Medicine and show promise for those who have been diagnosed with systemic lupus erythematosus (SLE). Sponsored by Biogen Inc., data from the phase 2 LILAC (Part A) clinical trial published this month shows that the experimental lupus therapy could reduce disease activity in the joints of patients, globa
Drug Topics
SEPTEMBER 23, 2022
World Health Organization said there is a lack of evidence of clinical effectiveness of the monoclonal antibodies Xevudy and Regen-Cov against the COVID-19 variants that are currently circulating.
Pharmacy Times
SEPTEMBER 19, 2022
Although there is no “best” way to determine which route of administration is best, health care providers are optimally positioned to educate patients and help them make the best decision.
STAT
SEPTEMBER 21, 2022
TORONTO — The Finks, married just a month earlier, sat down for their appointment, Kim dressed in head-to-toe pink and Chris in all black. He was taciturn, while she joked she couldn’t stop talking long enough to have her blood pressure taken. Jouvence Tshiyoyo Bukumba, a nurse, asked Kim, 46, about her cardiology appointment and Chris, 54, about his nerve pain.
Med Ed 101
SEPTEMBER 22, 2022
Serotonin syndrome and neuroleptic malignant syndrome (NMS) are two commonly taught drug-induced syndromes but are rarely encountered in practice. I wanted to put together some important differences between these two syndromes because many of the symptoms overlap. Some of those classic overlapping symptoms include hyperthermia, hypertension, and tachycardia.
Drug Topics
SEPTEMBER 22, 2022
The National Commission on Correctional Health Care and 166 other national organizations recently signed a letter to Senate leadership advocating for increased access to buprenorphine.
Pharmacy Times
SEPTEMBER 19, 2022
The most important thing you must do is listen to the patient, understand their concerns, and by doing that, you will gain their trust to be able to treat them appropriately.
STAT
SEPTEMBER 19, 2022
The overuse of antibiotics and other antimicrobials in raising farm animals for food may not be equivalent to Covid-19 and climate change as threats to human health, but it is right up there. This practice contributes to antibiotic-resistant infections, which are now a leading cause of death worldwide. The annual death toll from antimicrobial resistance could reach 10 million by 2050 — more people than currently die from cancer.
Drug Store News
SEPTEMBER 20, 2022
As more people seek out a multidimensional approach to health, interest in homeopathic medicine is on the rise.
Drug Topics
SEPTEMBER 22, 2022
A national study in Germany identified the baseline characteristics of patients with moderate-to-severe atopic dermatitis (AD) to understand how they are usually treated with Dupixent in the real world.
Pharmacy Times
SEPTEMBER 20, 2022
Study indicates that a diet high in ultra-processed food is more likely to increase the risk of colorectal cancer in men than it is women.
STAT
SEPTEMBER 22, 2022
Over the last six years, a venture capital team run out of pharmaceutical giant Bayer invested roughly $1.5 billion into small biotech startups. Now, it’s ramping up. The firm plans to invest a nearly identical pot of money — this time, $1.3 billion — in half the time.
European Pharmaceutical Review
SEPTEMBER 22, 2022
At Climate Week NYC GSK presented its new Sustainable Procurement Programme, announcing a fresh agenda, outlining how they will support their suppliers to succeed in their bold environmental objectives: have a net zero climate impact and a net positive impact on nature. This is an important move, as many GSK suppliers do not have easy geographical access to green infrastructure or green financing.
pharmaphorum
SEPTEMBER 22, 2022
BeiGene’s BTK inhibitor Brukinsa (zanubrutinib) has become the first drug in the class to be recommended for routine NHS use in England and Wales to treat Waldenström macroglobulinaemia (WM) – a rare form of non-Hodgkin lymphoma (NHL). The final appraisal document from health technology assessment (HTA) agency NICE says that Brukinsa can be used to treat WM in adults who have had at least one prior treatment, and only if bendamustine plus rituximab therapy is also suitable.
Pharmacy Times
SEPTEMBER 21, 2022
Pivotal top-line data demonstrate 20vPnC, if approved likely protects against 20 serotypes in 3-dose series and may offer the broadest serotype coverage of any PCV.
Expert insights. Personalized for you.
306 
Let's personalize your content